USOR 24232 - STAR Ph3 Study of NVL-655 Compared to Alectinib in First Line Tx with ALK+ NSCLC (ALKAZAR)

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

Disease Types: Lung - Non-Small Cell Lung, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Chicago, Niles